TICKERNOMICS Sign up
Last Update: 2023-12-23 06:03:49
SEELOS THERAPEUTICS INC. ( SEEL ) https://seelostherapeutics.com
1.48USD
Sector:
Healthcare
Industry:
Biotechnology
Country:
United States
1y
3y
5y
10y
Historical Returns*:
SPY
23.45%
-92.95%
SEEL
SPY
30.72%
-97.55%
SEEL
SPY
112.82%
-99.13%
SEEL
SPY
201.04%
-99.99%
SEEL
*Assumes dividends reinvested
Market Stats:
Market Capitalization($MM)
Enterprise Value($MM)
Daily Volume(MM)
219.25
249.17
0.34
Valuation Metrics:
Price/Earnings Ratio
Price/Sales Ratio
Price/Book Value
FCF Yield(%)
Dividend Yield(%)
EV/EBITDA
-3.96
113.89
-7.21
-2.85
0.00
-4.96
Profitability Stats:
Operating Margin %(ttm)
Gross Profit %(ttm)
EBITDA Margin %(ttm)
-3104.19
100.00
-2569.63
Shareholder Value Creation:
Cost of Capital %(est)
ROIC %(ttm)
ROCE %(ttm)
Beta
-14.0662
-115.77
-123.87
-4.33
Other Earnings and Cash Flow Stats:
SEELOS THERAPEUTICS INC. ( SEEL ) Net Income TTM ($MM) is -47.60
SEELOS THERAPEUTICS INC. ( SEEL ) Operating Income TTM ($MM) is -57.20
SEELOS THERAPEUTICS INC. ( SEEL ) Owners' Earnings Annual ($MM) is 0.00
SEELOS THERAPEUTICS INC. ( SEEL ) Current Price to Owners' Earnings ratio is 0.00
SEELOS THERAPEUTICS INC. ( SEEL ) EBITDA TTM ($MM) is -58.83
SEELOS THERAPEUTICS INC. ( SEEL ) EBITDA Margin is -2569.63%
Capital Allocation:
SEELOS THERAPEUTICS INC. ( SEEL ) has paid 0.00 dividends per share and bought back -41.448797 million shares in the past 12 months
SEELOS THERAPEUTICS INC. ( SEEL ) has increased its debt by 0.459 million USD in the last 12 months
Capital Structure:
SEELOS THERAPEUTICS INC. ( SEEL ) Interest-bearing Debt ($MM) as of last quarter is 32
SEELOS THERAPEUTICS INC. ( SEEL ) Annual Working Capital Investments ($MM) are 6
SEELOS THERAPEUTICS INC. ( SEEL ) Book Value ($MM) as of last quarter is -31
SEELOS THERAPEUTICS INC. ( SEEL ) Debt/Capital as of last quarter is -107%
Other Balance Sheet Stats:
SEELOS THERAPEUTICS INC. ( SEEL ) has 2 million in cash on hand as of last quarter
SEELOS THERAPEUTICS INC. ( SEEL ) has 35 million of liabilities due within 12 months, and long term debt 16 as of last quarter
SEELOS THERAPEUTICS INC. ( SEEL ) has 148 common shares outstanding as of last quarter
SEELOS THERAPEUTICS INC. ( SEEL ) has 0 million USD of preferred stock value
Academic Scores:
SEELOS THERAPEUTICS INC. ( SEEL ) Altman Z-Score is -84.30 as of last quarter
SEELOS THERAPEUTICS INC. ( SEEL ) Piotroski Score is 5.00 as of last quarter
Corporate Governance:
SEELOS THERAPEUTICS INC. ( SEEL ) largest shareholder is Morgan Stanley - Brokerage Accounts owning 497380 shares at 0.74 ($MM) value
Daniel J O'connor(an insider) Bought 533 shares of SEELOS THERAPEUTICS INC. ( SEEL ) for the amount of $9753.90 on 2022-06-01
2.81% of SEELOS THERAPEUTICS INC. ( SEEL ) is held by insiders, and 20.36% is held by institutions
SEELOS THERAPEUTICS INC. ( SEEL ) went public on 1999-04-19
Other SEELOS THERAPEUTICS INC. ( SEEL ) financial metrics:
FCF:-40.29
Unlevered Free Cash Flow:0.00
EPS:0.28
Operating Margin:-3104.19
Gross Profit Margin:100.00
Div. Payout Ratio%:0.00
Div. Growth YoY%:0.00
Equity Return%:-138.08
Beta:-4.33
Buffet's Owners Earnings:0.00
Price to Owner's Earnings:0.00
About SEELOS THERAPEUTICS INC. ( SEEL ) :
Seelos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for the treatment of central nervous system, respiratory, and other disorders. The company's lead programs are SLS-002, an intranasal racemic ketamine for the treatment of acute suicidal ideation and behavior in patients with major depressive disorders; SLS-005, a protein stabilizer for the treatment of amyotrophic lateral sclerosis and Sanfilippo syndrome; and SLS-006, a partial dopamine agonist for the treatment of patients with Parkinson's disease (PD). Its preclinical programs include SLS-007, a peptidic inhibitor to treat patients with PD; SLS-008 for the treatment of pediatric indications; SLS-004 for the treatment of PD; SLS-010, an H3 receptor antagonist; and SLS-012. The company was founded in 2016 and is headquartered in New York, New York.
User Content from Tickernomics. Created by Luminus.
DISCLAIMER

This web site and its creators are not certified financial advisors. All opinions/suggestions expressed on this website should not be treated as specific inducement to make a particular investment or follow a particular strategy, but only as an expression of an opinion.The Company doesn't warrant the information provided on the website for its completeness or accuracy, and it should not be relied upon as such. The Company is not under any obligation to update or correct any information provided on this website.The content of this website is published in the United States of America and persons who access it agree to do so in accordance with applicable U.S. law.Past performance is not indicative of future results. The Company doesn't guarantee any specific outcome or profit. You should be aware of the real risk of loss in following any strategy or investment discussed on this website.Strategies or investments discussed may fluctuate in price or value. Investors may get back less than invested. Investments or strategies mentioned on this website may not be suitable for you. This material does not take into account your particular investment objectives,financial situation or needs and is not intended as recommendations appropriate for you. You must make an independent decision regarding investments or strategies mentioned on this website. Before acting on information on this website, you should consider whether it is suitable for your particular circumstances and strongly consider seeking advice from your own financial or investment adviser.